Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vatalanib with Temozolomide and Radiotherapy in Newly Diagnosed GBM
NCT00128700Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jun 2005
- Primary completion
- Nov 2007
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of vatalanib in glioblastoma multiforme (GBM) (3 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Maximum Tolerated Dose and Progression-Free Survival at 6 months. Started Jun 2005; status: completed.
02
Drugs
vatalanib
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00128700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00128700.